The mammary epithelium contains the oestrogen receptor alpha (ERα), which is crucial for the development of breast cancer and endocrine therapy. The majority of breast cancers about two thirds overexpress ERα, making them more responsive to hormone therapy and giving them a better prognosis than tumours that express ERα infrequently or not at all. Anti-estrogens have been demonstrated to prevent the growth of breast cancer cells by out-competing oestrogen for binding to nuclear receptors. The tumour grow in response to the oestrogen hormone are termed as ER- Positive breast cancer. The majority of breast cancers about 80% are ER-positive. Because of their ability to inhibit cell proliferation, 9-aminoactridines are important DNA-intercalating agents. The Schrodinger suit's Prime-MM-GB/SA module does binding free energy calculations, the Glide module conducts in-silico ADMET screening, and the QikProp module performs molecular docking studies for the 26 designed compounds 1a–z. Based on the GLIDE score, the binding affinity of the created compounds 1a–z towards ER was selected.